CA3086457A1 — Medicament comprising combination of sepetaprost and rho-associated coiled-coil containing protein kinase inhibitor
Assigned to Santen Pharmaceutical Co Ltd · Expires 2019-06-27 · 7y expired
What this patent protects
The purpose of the present invention is to identify a combination of drugs for the prevention or treatment of glaucoma or ocular hypertension, said combination being useful as a prophylactic or therapeutic agent for glaucoma or ocular hypertension. Combining sepetaprost and an Rh…
USPTO Abstract
The purpose of the present invention is to identify a combination of drugs for the prevention or treatment of glaucoma or ocular hypertension, said combination being useful as a prophylactic or therapeutic agent for glaucoma or ocular hypertension. Combining sepetaprost and an Rho-kinase inhibitor enhances the intraocular pressurelowering effect in comparison to when either drug is used alone. The drugs may be administered concurrently or as a combination drug.
Drugs covered by this patent
- Xalatan (LATANOPROST) · Thea Pharma
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.